RxDoctor Payments Data

Sterling Dubin, MD

Gastroenterology · San Diego, CANPI 1215223474

Payments from drug & device makers

$3,027in general payments, 2019–2025

Across 155 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$978
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$466
  • Johnson & Johnson$414
  • Bristol Myers Squibb$227
  • Pfizer$131
  • Takeda Pharmaceuticals U.S.A., Inc.$128
  • plus $683 from 14 others

What the payments were for

  • Consulting fees$642%
  • Food & beverage$2,79992%
  • Education$1645%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,027 in reported general payments places this provider in the 55th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$130,426
Medicare patients
428
Services billed
884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin22$48,388
VemlidyTenofovir Alafenamide14$31,257
CreonLipase/Protease/Amylase15$18,773
LinzessLinaclotide29$18,355
MotegrityPrucalopride Succinate14$16,850
Mesalamine24$13,075
SutabSod Sulf/Pot Chloride/Mag Sulf79$12,738
DexilantDexlansoprazole13$5,493
Dexlansoprazole DrDexlansoprazole24$5,376
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates33$1,865
Colestipol Hcl19$1,668
Pantoprazole Sodium64$1,254
Omeprazole95$1,243
Famotidine55$814
Ondansetron OdtOndansetron158$535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$466$48,38822 claims
AbbVieCreon, Linzess$978$37,12744 claims
GileadVemlidy$45$31,25714 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant$128$22,34327 claims
Braintree Laboratories, Inc.Sutab$63$12,73879 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →